Prachi R. Patel

Prachi R. Patel

Auto-generated profile, based on publicly available information

Prachi R. Patel

Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
DSDivanshu Shukla
Divanshu Shukla
KGKhatuna Gabunia
Khatuna Gabunia
SMShannon E. McGettigan
Shannon E. McGettigan
PPPrachi R. Patel
Prachi R. Patel
SCShannon Christensen
Shannon Christensen
JRJames L. Riley
James L. Riley
Patients can develop human anti-mouse immune responses against CD19-specific chimeric antigen receptor (CAR) T cells due to the use of a murine CD19-specific single-chain variable fragment to redirect T cells. We screened a yeast display library to identify an array of fully human CD19 single-chain variable fragment binders and performed a series of studies to select the most promising fully human CAR. We observed significant differences in the ability of CARs employing these CD19 binders to be expressed on the cell surface, induce tonic signaling, redirect T-cell function, mediate tumor killing, recognize lower levels of CD19 antigen, and maintain function upon continuous antigen exposure. From this initial analysis, CAR T cells using two binders (42 and 52) were selected for additional studies. Although CAR T cells using both binders controlled tumor growth well in vivo, we advanced a CAR construct using binder 42 for more advanced preclinical testing because of its greater similarity to binders based on the antibody FMC63, which is the murine antibody underlying four FDA-approved CD19-specific CAR T-cell therapies, and ability to robustly respond to tumors expressing lower levels of CD19. We found that this binder uniquely bound CD19 using distinct contact residues than FMC63 and with ∼40-fold lower affinity. CARs using binder 42 were non-inferior to those using the FMC63 binder in a mouse model of acute lymphoblastic leukemia, indicating that CAR T cells using binder 42 should be considered for clinical use.

4 June 2025
Verified
Other
Open access
DSDivanshu Shukla
Divanshu Shukla
KGKhatuna Gabunia
Khatuna Gabunia
SMShannon E. McGettigan
Shannon E. McGettigan
PPPrachi R. Patel
Prachi R. Patel
SCShannon Christensen
Shannon Christensen
JRJames L. Riley
James L. Riley
Supplemental Figure 4: In the validation titration experiment, the isotype control article was screened for binding against targets identified on the MPA screen as well as the positive controls (Protein A and a known binder CD19), and the negative control (pUC empty Vector) expressed in HEK-293T cells. The isotype control article showed strong binding to Protein A, as expected, there was no binding of the control article to CD19 or any of the other targets evaluated. The isotype control article was screened at four different concentrations, as mentioned at x-axis. Each legend shows the targets that the isotype control article was screened against.

4 June 2025
Verified
Other
Open access
DSDivanshu Shukla
Divanshu Shukla
KGKhatuna Gabunia
Khatuna Gabunia
SMShannon E. McGettigan
Shannon E. McGettigan
PPPrachi R. Patel
Prachi R. Patel
SCShannon Christensen
Shannon Christensen
JRJames L. Riley
James L. Riley
Supplemental Figure 2: a) Survival curve of mice after CART cell treatment. b-d) Peripheral blood was collected from humanized mice on the indicated days after CART treatment and stained with anti-human CD45, CD3, CD4, CD8 antibodies, and CD19 protein. As indicated, mice were re-challenged with 1M Jeko-1-CBG-GFP 42 days after CART infusion.

4 June 2025
Verified
Other
Open access
DSDivanshu Shukla
Divanshu Shukla
KGKhatuna Gabunia
Khatuna Gabunia
SMShannon E. McGettigan
Shannon E. McGettigan
PPPrachi R. Patel
Prachi R. Patel
SCShannon Christensen
Shannon Christensen
JRJames L. Riley
James L. Riley
Patients can develop human anti-mouse immune responses against CD19-specific chimeric antigen receptor (CAR) T cells due to the use of a murine CD19-specific single-chain variable fragment to redirect T cells. We screened a yeast display library to identify an array of fully human CD19 single-chain variable fragment binders and performed a series of studies to select the most promising fully human CAR. We observed significant differences in the ability of CARs employing these CD19 binders to be expressed on the cell surface, induce tonic signaling, redirect T-cell function, mediate tumor killing, recognize lower levels of CD19 antigen, and maintain function upon continuous antigen exposure. From this initial analysis, CAR T cells using two binders (42 and 52) were selected for additional studies. Although CAR T cells using both binders controlled tumor growth well in vivo, we advanced a CAR construct using binder 42 for more advanced preclinical testing because of its greater similarity to binders based on the antibody FMC63, which is the murine antibody underlying four FDA-approved CD19-specific CAR T-cell therapies, and ability to robustly respond to tumors expressing lower levels of CD19. We found that this binder uniquely bound CD19 using distinct contact residues than FMC63 and with ∼40-fold lower affinity. CARs using binder 42 were non-inferior to those using the FMC63 binder in a mouse model of acute lymphoblastic leukemia, indicating that CAR T cells using binder 42 should be considered for clinical use.


4 June 2025
Verified
Other
Open access
DSDivanshu Shukla
Divanshu Shukla
KGKhatuna Gabunia
Khatuna Gabunia
SMShannon E. McGettigan
Shannon E. McGettigan
PPPrachi R. Patel
Prachi R. Patel
SCShannon Christensen
Shannon Christensen
JRJames L. Riley
James L. Riley
Supplemental Figure 1: a-b) Primary human T cells stimulated using anti-CD3/28 beads and on the following day were transduced with indicated CARs. Cells were stained with G4S linker antibody (a) and FITC-labeled human CD19 protein (b). c) After 12 days of culture, CAR expression was evaluated using FITC-labeled human CD19 protein.